Business
Theralase Releases 2019 Annual General Meeting Video Presentations
TORONTO, ON / ACCESSWIRE / June 28, 2019 / Theralase ® Technologies Inc. (" Theralas...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Releases 2019 Annual General Meeting Video PresentationsTORONTO, ON / ACCESSWIRE / June 28, 2019 / Theralase® Technologies Inc. (\"Theralase\" or the \"Company\") (TLT:TSXV) (TLTFF:OTCQB), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (\"PDCs\") and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to release the video presentations of this year's Annual General Meeting (\"AGM\"). The AGM was held at Theralase's corporate office in Toronto, Ontario on June 27, 2019 and is available at https://youtu.be/Y_gWz2XvhuUThe pre-recorded videos feature Dr. Girish Kulkarni, Assistant Professor with the Department of Surgery, Faculty of Medicine at the University of Toronto, Uro-Oncologist and Principal Investigator (\"PI\"), University Health Network (\"UHN\") discussing the successful completion of the Phase Ib Non-Muscle Invasive Bladder Cancer (\"NMIBC\") clinical study (\"ACT-NMIBC\") and Dr. Michael Jewett, Professor of Surgery (Urology) at the University of Toronto and Uro-oncologist at Princess Margaret Cancer Centre, UHN discussing the ACT-NMIBC clinical study design.Shawn Shirazi, Ph.D., CEO - Drug Division, Theralase stated that, \"The Company is pleased to work with Dr. Jewett and Dr. Kulkarni, with their vast expertise in the field of uro-oncology on this clinical study. Their experience and guidance have been indispensable in assisting Theralase to launch the Phase II ACT-NMIBC study. The successfully completed Phase Ib NMIBC clinical study demonstrated Complete Response (\"CR\") in two patients treated at the therapeutic dose (0.70 mg/cm2) at 360 days post initial single treatment. The Company has been extremely pleased with the performance of our patented study drug (TLD-1433) and study device (TLC-3200) in the Phase Ib NMIBC clinical study and believe we are able to achieve comparable results in a Phase II NMIBC clinical study.\"Kipton Lade, B.Sc., M.Sc. MBA, CEO - Device Division, Theralase stated that, \"It is remarkable what the Company has been able to accomplish, with the assistance of Dr. Jewett and Dr. Kulkarni. Now that the ACT-NMIBC clinical study has commenced, UHN is actively screening patients for enrollment, while Theralase is busy onboarding additional Canadian s...